title: Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
abstract: Fourteen postmenopausal women with estrogen-receptor positive advanced breast cancer and no prior cytostatic treatment received 20 mg toremifene daily as a single dose after a loading dose (120----60----60 mg) for the first 3 days. All were evaluable and had undergone at least 6 weeks' treatment. Results were: no complete remissions (CR), 3 partial remissions (PR), 8 no change (NC) and 3 cases of progressive disease (PD). Three patients had mild side effects: nausea, insomnia, sweating and arm pain.
authors: Department of Radiotherapy and Oncology, Helsinki, University Central Hospital, Finland.
authors: S
authors: S
authors: Pyrhönen
authors: R
authors: R
authors: Valavaara
authors: M
authors: M
authors: Heikkinen
authors: P
authors: P
authors: Rissanen
authors: G
authors: G
authors: Blanco
authors: E
authors: E
authors: Nordman
authors: L R
authors: LR
authors: Holsti
authors: A
authors: A
authors: Hajba
mesh_terms: D000368:Aged; D001799:Blood Sedimentation / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017312:Toremifene
chemical_list: D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene